ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

New Technique Enables Safer Gene-Editing Therapy Using CRISPR – UT News | The University of Texas at Austin

Continue reading

2017-06-29 Michael Zand NEWS

New study reveals key steps in CRISPR-Cas3 function at near-atomic resolution – Phys.Org


UT News | The University of Texas at Austin

New Technique Enables Safer Gene-Editing Therapy Using CRISPR
UT News | The University of Texas at Austin
Scientists already use the gene-editing tool called CRISPR to edit the genetic code of nearly any organism. CRISPR-based gene editing will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are …
Gene Editing Reverses Huntington’s in Mouse StudyBioscience Technology

all 3 news articles »

Continue reading

2017-06-29 Michael Zand NEWS

New technique enables safer gene-editing therapy using CRISPR – Phys.Org

Phys.OrgNew technique enables safer gene-editing therapy using CRISPRPhys.OrgA CRISPR protein targets specific sections of DNA and cuts them. Scientists have turned this natural defense mechanism in bacteria into a tool for gene editing. Credit: Jenna … Continue reading

2017-06-29 Michael Zand NEWS

Eiger sells gene therapy candidate Mydicar to Theragene for $3.1M in cash and stock – Seeking Alpha

Pharmaceutical ProcessingEiger sells gene therapy candidate Mydicar to Theragene for $3.1M in cash and stockSeeking AlphaMydicar is a cardiovascular gene therapy product that employs an adeno-associated virus (AAV) to deliver a certain protein to cardi… Continue reading

2017-06-29 Michael Zand NEWS

First-Line Immunotherapy Beneficial in Specific Patient Subset with Advanced Lung Cancer – Specialty Pharmacy Times


Phys.Org

New study reveals key steps in CRISPR-Cas3 function at near-atomic resolution
Phys.Org
Cryo-electron microscope image of CRISPR in a full ‘R-loop’ conformation. DNA (orange and red) is unwound and compared to CRISPR RNA (blue), to determine if the target DNA should be cut by the Cas3 enzyme. Credit: Liao lab/Harvard Medical School.
New gene-editing tool could cure disease. Or customize kids. Or aid bioterrorism.Washington Post

all 1 news articles »

Continue reading

2017-06-29 Michael Zand NEWS

Functional blood progenitors for mouse and man – Nature.com

Functional blood progenitors for mouse and manNature.comBlood research and therapeutics for blood disorders would greatly benefit from a ready source of stem and progenitor cells. Although hematopoietic stem cells (HSCs) have been produced by many rout… Continue reading

2017-06-29 Michael Zand NEWS

Functional blood progenitors for mouse and man – Nature.com

Functional blood progenitors for mouse and manNature.comBlood research and therapeutics for blood disorders would greatly benefit from a ready source of stem and progenitor cells. Although hematopoietic stem cells (HSCs) have been produced by many rout… Continue reading

2017-06-29 Michael Zand NEWS

Biotech Gene Therapy Names Juno, Kite, And bluebird bio Still Have Room To Run – Seeking Alpha

Biotech Gene Therapy Names Juno, Kite, And bluebird bio Still Have Room To RunSeeking AlphaThis report highlights a trio of gene therapy names with additional upside for investors with an 18-month time horizon. BLUE should net at least $150,000 per pat… Continue reading

2017-06-29 Michael Zand NEWS
  • 1
  • …
  • 1,561
  • 1,562
  • 1,563
  • 1,564
  • 1,565
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

First-Line Immunotherapy Beneficial in Specific Patient Subset with Advanced Lung Cancer
Specialty Pharmacy Times
“This study is an important step toward understanding the impact of tumor mutation burden and PD-L1 in immunotherapy response,” said lead investigator David Carbon, MD, PhD. “This data shows we should evaluate these 2 factors independently to most …